Genocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020
Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy
100% of patients have immune responses to ATLAS-identified neoantigens
ESMO E-POSTER PRESENTATION:
Title: Preliminary results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumor specific neoantigens, in combination with PD-1 inhibitors in advanced cancers
Link to the poster: https://www.esmo.org/meetings/esmo-virtual-congress-2020/registration?hit=ehp
The results build on the Part B findings shared previously, which evaluated the preliminary immunogenicity and efficacy of GEN-009 in combination with standard-of-care checkpoint inhibitor-based regimens (CPI) in an initial cohort of five patients with advanced solid tumors. All five patients received GEN-009 approximately four months following the start of CPI treatment.
New follow-up scans, ranging from 91-233 days post-vaccination, confirm the previously disclosed findings, with tumor reduction or stable outcomes for all five patients, including three RECIST-criteria changes in tumor size (2 PR, 1 CR) after vaccination and likely attributable to GEN-009. The new results continue to suggest GEN-009 vaccination could be used in conjunction with CPI-based therapies to augment their effects. In addition, 100 percent of patients had neoantigen-specific responses elicited by vaccination, in some cases with evidence of epitope spread. No significant adverse side effects were reported, with only mild symptoms associated with the vaccine adjuvant.
“The step-down response curves represent a promising and previously unobserved pattern of tumor response that warrants further investigation,” said
“Our findings, which show that RECIST responses were maintained for at least three months in three of the five patients evaluated, underscore the potential of GEN-009 to boost CPI regimens in hard to treat patients,” said Thomas Davis, M.D., Chief Medical Officer of Genocea. “We believe that the path forward to designing better immunotherapies is powered by ATLAS. These results build further confidence that we are indeed targeting relevant tumor antigens for inclusion in our GEN-009 vaccine.”
The company expects to share additional immunogenicity and clinical data from the remaining 10 Part B patients later this year.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we expect to conduct a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended
Source: Genocea Biosciences, Inc.